Epstein-Barr virus distribution in nonneoplastic lymph nodes. 1993

F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
Department of Pathology, City of Hope National Medical Center, Duarte, California.

Epstein-Barr virus (EBV) has been associated with a wide variety of neoplastic conditions including nasopharyngeal carcinoma, gastric carcinoma, lymphoproliferative disorders in immunocompromised hosts, Hodgkin's disease, and non-Hodgkin's lymphomas of either B or T-cell phenotype. Although the presence of EBV in neoplastic lymph nodes has been well studied, very few studies have examined the distribution of EBV in normal or reactive lymph nodes. We studied normal or reactive lymph nodes from patients in Peru, a geographical region with a relatively high prevalence of EBV infection as compared with the United States or Europe. EBV DNA-RNA in situ hybridization was performed using a 30-base biotinylated oligonucleotide complementary to the EBER1 gene of EBV. Ten cases showed the presence of EBV RNA in scattered cells (less than 50 per section) and were utilized in the study. Most of the cells labeling for EBV RNA were small lymphocytes although some large lymphocytes also labeled. These cases were then subjected to double-labeling immunohistochemical/in situ hybridization studies using monoclonal antibodies L26(CD20), Leu22(CD43), Leu7(CD57), and the polyclonal antibody CD3. In their respective sections, of those cells that showed positive labeling for EBV RNA, 44% double labeled for L26, 24% double labeled for CD3, and 23% double labeled for Leu22. No cells double labeled for Leu7. This study shows that EBV RNA is expressed in both B and T-cells in nonneoplastic lymph nodes. These findings are compatible with other studies that have shown the presence of EBV in both B and T-cell non-Hodgkin's lymphomas.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007223 Infant A child between 1 and 23 months of age. Infants
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008206 Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS. Lymphatism,Status Lymphaticus,Disease, Lymphatic,Diseases, Lymphatic,Lymphatic Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious

Related Publications

F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
April 1997, Pathology international,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
June 1996, Cancer,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
October 1996, Journal of virology,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
November 2002, Journal of virology,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
November 1992, Leukemia & lymphoma,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
December 1993, Postgraduate medical journal,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
November 1993, International journal of cancer,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
January 1979, Nouvelle revue francaise d'hematologie,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
April 2007, Leukemia & lymphoma,
F D Deamant, and P F Albújar, and Y Y Chen, and L M Weiss
June 2005, Journal of clinical pathology,
Copied contents to your clipboard!